Literature DB >> 22884754

Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.

Roberto Roiz-Santiáñez1, Diana Tordesillas-Gutiérrez, Victor Ortíz-García de la Foz, Rosa Ayesa-Arriola, Agustín Gutiérrez, Rafael Tabarés-Seisdedos, José Luis Vázquez-Barquero, Benedicto Crespo-Facorro.   

Abstract

BACKGROUND: Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time. The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis. We aimed to investigate the effects of low doses of haloperidol, risperidone and olanzapine on cortical thickness.
METHOD: We investigated the effects of risperidone (N=16), olanzapine (N=18) and low doses of haloperidol (N=18) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients. The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed. A group of 45 healthy volunteers was also longitudinally evaluated. Magnetic resonance imaging brain scans (1.5T) were obtained and images were analyzed by using BRAINS2.
RESULTS: There were no significant effects of time (F(1,47)<1.66; P>0.204), treatment group (F(2,47)<1.47; P>0.242) or group-by-time interaction (F(2,47)<1.82; P>0.174) for any of the cortical thickness variables. When the group of healthy controls was included in the analyses, it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level (F(3,81)=2.686; P=0.052). After the Bonferroni adjustment for multiple comparisons, there were no significant associations between changes in cortical thickness and clinical and cognitive outcome.
CONCLUSIONS: Low doses of haloperidol, risperidone, and olanzapine seem to equally affect gray matter cortical thickness, overall and lobes, at the medium-term (1 year). The clinical effectiveness of treatments was not significantly related to changes in cortical thickness.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884754     DOI: 10.1016/j.schres.2012.07.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

1.  [Can long-term treatment with antipsychotic drugs lead to structural brain damage? Pro].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2013-09       Impact factor: 1.214

Review 2.  Neuroimaging markers of antipsychotic treatment response in schizophrenia: An overview of magnetic resonance imaging studies.

Authors:  Goda Tarcijonas; Deepak K Sarpal
Journal:  Neurobiol Dis       Date:  2018-06-25       Impact factor: 5.996

Review 3.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

4.  Exploring cortical predictors of clinical response to electroconvulsive therapy in major depression.

Authors:  Mike M Schmitgen; Katharina M Kubera; Malte S Depping; Henrike M Nolte; Dusan Hirjak; Stefan Hofer; Julia H Hasenkamp; Ulrich Seidl; Bram Stieltjes; Klaus H Maier-Hein; Fabio Sambataro; Alexander Sartorius; Philipp A Thomann; Robert C Wolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-07-05       Impact factor: 5.270

5.  Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.

Authors:  Giulia Tronchin; Theophilus N Akudjedu; Mohamed Ahmed; Laurena Holleran; Brian Hallahan; Dara M Cannon; Colm McDonald
Journal:  Neuropsychopharmacology       Date:  2020-04-08       Impact factor: 7.853

Review 6.  Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective.

Authors:  Stephen M Lawrie
Journal:  Ther Adv Psychopharmacol       Date:  2018-06-15

7.  Response to targeted cognitive training may be neuroprotective in patients with early schizophrenia.

Authors:  Ian S Ramsay; Susanna Fryer; Brian J Roach; Alison Boos; Melissa Fisher; Rachel Loewy; Judith M Ford; Sophia Vinogradov; Daniel H Mathalon
Journal:  Psychiatry Res Neuroimaging       Date:  2021-04-07       Impact factor: 2.493

Review 8.  Brain Structural Effects of Antipsychotic Treatment in Schizophrenia: A Systematic Review.

Authors:  Roberto Roiz-Santiañez; Paula Suarez-Pinilla; Benedicto Crespo-Facorro
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

9.  The impact of genome-wide supported schizophrenia risk variants in the neurogranin gene on brain structure and function.

Authors:  Esther Walton; Daniel Geisler; Johanna Hass; Jingyu Liu; Jessica Turner; Anastasia Yendiki; Michael N Smolka; Beng-Choon Ho; Dara S Manoach; Randy L Gollub; Veit Roessner; Vince D Calhoun; Stefan Ehrlich
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.